Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741307 | 0.77 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL20741308 | 0.77 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL9625236 | 0.77 | ESR1 (0.42) | — | |
| SCHEMBL1855200 | 0.74 | — | — | |
| SCHEMBL30748960 | 0.74 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL15332425 | 0.74 | ALDH1A1 (0.35) | KDM4EALDH1A1FDPS | |
| SCHEMBL2563540 | 0.74 | ALDH1A1 (0.35) | KDM4EALDH1A1FDPS | |
| SCHEMBL1063041 | 0.74 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL589541 | 0.74 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL2588895 | 0.74 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CPLAUS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| EP-2471787-A1 | New compounds | Boehringer Ingelheim International GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2324012-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263565-A1 | COMPOUNDS | MKI67, CCNA1, CCNT1 | ADRA2A 1185/4885ADRA2B 1141/4885ADRA2C 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.